Literature DB >> 15341691

Remission and regression of diabetic nephropathy.

Peter Hovind1, Lise Tarnow, Hans-Henrik Parving.   

Abstract

Diabetic kidney disease is considered to be an irreversible and inexorable progressive disease. Therefore, prevention of development of ESRD is extremely important. Animal studies have demonstrated that regression of existing renal morphologic lesions is feasible. In a sizable fraction of type 1 diabetic patients with overt nephropathy, remission (decrease in albuminuria to <300 mg/24 h) was obtained (31%), and regression of diabetic nephropathy (rate of decline in GFR < or = 1 mL/min/y), achieved (22%) by aggressive antihypertensive treatment. Furthermore, remission of nephrotic-range albuminuria (from >2500 mg/24 h to <600 mg/24 h) have been demonstrated to be achievable in one fifth of patients with nephrotic-range albuminuria. Remission of nephrotic-range albuminuria was associated with a reduction in decline in GFR and improved survival free of ESRD. However, to prevent development of ESRD in diabetic patients, an aggressive multifactorial approach, aiming at lowering blood pressure and albuminuria, and improving glycemic control, must be applied.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341691     DOI: 10.1007/s11906-004-0057-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  44 in total

Review 1.  Use of gene markers to guide antihypertensive therapy.

Authors:  S T Turner; G L Schwartz; A B Chapman; E Boerwinkle
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

2.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

Authors:  P Gaede; P Vedel; H H Parving; O Pedersen
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

3.  Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1976-07       Impact factor: 1.713

4.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

5.  Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.

Authors:  W A Wilmer; L A Hebert; E J Lewis; R D Rohde; F Whittier; D Cattran; A S Levey; J B Lewis; S Spitalewitz; S Blumenthal; R P Bain
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

6.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

7.  The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus.

Authors:  K Borch-Johnsen; P K Andersen; T Deckert
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

8.  Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.

Authors:  Marcin Adamczak; Marie-Luise Gross; Jan Krtil; Andreas Koch; Karin Tyralla; Kerstin Amann; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

9.  Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.

Authors:  H H Parving; A R Andersen; U M Smidt; P A Svendsen
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

10.  Monitoring glomerular function in diabetic nephropathy. A prospective study.

Authors:  G C Viberti; R W Bilous; D Mackintosh; H Keen
Journal:  Am J Med       Date:  1983-02       Impact factor: 4.965

View more
  7 in total

1.  Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy.

Authors:  Marie-Luise Brezniceanu; Cara J Lau; Nicolas Godin; Isabelle Chénier; Alain Duclos; Jean Ethier; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 10.121

Review 2.  Sex, diabetes and the kidney.

Authors:  Christine Maric
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14

3.  Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes.

Authors:  Meda E Pavkov; William C Knowler; Robert L Hanson; Peter H Bennett; Robert G Nelson
Journal:  Am J Kidney Dis       Date:  2008-03-20       Impact factor: 8.860

Review 4.  Estrogens and the diabetic kidney.

Authors:  Christine Maric; Shannon Sullivan
Journal:  Gend Med       Date:  2008

5.  Imbalance in sex hormone levels exacerbates diabetic renal disease.

Authors:  Qin Xu; Corinne C Wells; Joseph H Garman; Laureano Asico; Crisanto S Escano; Christine Maric
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

6.  ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy.

Authors:  Bo Zheng; Lei Chen; Frank J Gonzalez
Journal:  Kidney Int Rep       Date:  2016-08-05

7.  Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression.

Authors:  Tatsuo Yanagawa; Keiko Koyano; Koichiro Azuma
Journal:  Diabetol Int       Date:  2021-01-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.